Highland Peak Capital LLC Sells 81,440 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Highland Peak Capital LLC trimmed its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.4% in the third quarter, HoldingsChannel.com reports. The fund owned 573,785 shares of the company’s stock after selling 81,440 shares during the quarter. Teva Pharmaceutical Industries comprises approximately 3.8% of Highland Peak Capital LLC’s portfolio, making the stock its 10th biggest position. Highland Peak Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $11,590,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Phoenix Financial Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. National Pension Service raised its position in shares of Teva Pharmaceutical Industries by 24.2% in the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after buying an additional 404,526 shares during the last quarter. Oak Harvest Investment Services purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $1,010,000. Public Sector Pension Investment Board lifted its stake in shares of Teva Pharmaceutical Industries by 11.5% during the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after buying an additional 69,000 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its position in Teva Pharmaceutical Industries by 12.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 767,870 shares of company stock worth $23,888,014 over the last quarter. 0.49% of the stock is owned by corporate insiders.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Blackstone Life Sciences agreed to provide $400 million to fund development of duvakitug (TL1A antibody), lowering capital risk for Teva’s late‑stage IBD program and accelerating a potential new specialty biologic growth engine. Teva, Blackstone Life Sciences Enter $400M Funding Agreement for Duvakitug
• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and nudged its price target higher to $41, signaling continued analyst confidence and providing a visible upside reference for investors. Benzinga coverage of Piper Sandler
• Neutral Sentiment: Coverage highlighting generic-drug headwinds also notes Teva’s strategic push into complex generics and biosimilars as a hedge against price pressure—this supports longer-term growth but doesn’t remove near-term margin risk. 3 Generic Drug Stocks to Watch Despite Industry Headwinds
• Neutral Sentiment: Broader industry commentary about AI adoption in pharma could benefit Teva over time through R&D efficiency and manufacturing optimization, but it’s a longer‑horizon factor rather than an immediate catalyst. Pharmaceutical Executive Daily: Pharma Industry’s AI Adoption
• Negative Sentiment: An executive (EVP Eliyahu Sharon Kalif) disclosed a large sale of 345,810 shares (~$11.6M at the trade price), which can be interpreted by some investors as insider profit‑taking and can weigh on sentiment. Teva EVP Sells 345,810 Shares
• Negative Sentiment: High‑profile investor Stanley Druckenmiller trimmed his TEVA position per 13F filings, a notable name‑level reduction that can be read as profit‑taking and may reduce momentum among discretionary institutional buyers. Billionaire Stanley Druckenmiller Dumped Teva
• Negative Sentiment: A dividend-focused piece recommends an alternative high-yield competitor over Teva, which could damp demand from income investors who are comparing yields and stability. Forget Teva: This Dividend Top Dog Is the Real Value Buy Today

Teva Pharmaceutical Industries Stock Up 1.8%

TEVA stock opened at $32.87 on Thursday. The company has a market capitalization of $37.79 billion, a P/E ratio of 27.39, a PEG ratio of 10.80 and a beta of 0.72. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The firm has a 50 day simple moving average of $33.03 and a 200-day simple moving average of $26.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on TEVA. Scotiabank boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.